Phaseline

Companies › Shanghai Mabgeek Biotech.Co.Ltd

Shanghai Mabgeek Biotech.Co.Ltd: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Respiratory, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MG-K10 Humanized Monoclonal Antibody Injection
Humanized monoclonal antibody
–Phase 3Prurigo Nodularis; Asthma; Seasonal Allergic Rhinitis; Atopic DermatitisNov 2026
MG-ZG122 Humanized Monoclonal Antibody Injection
Humanized monoclonal antibody
–Phase 2Bronchial AsthmaMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06765005MG-K10 Humanized Monoclonal Antibody InjectionPhase 1Atopic DermatitisImmunologyMay 2025
NCT06846385MG-K10 Humanized Monoclonal Antibody InjectionPhase 2Seasonal Allergic RhinitisImmunologyMay 2025
NCT06779136MG-K10 Humanized Monoclonal Antibody InjectionPhase 3Prurigo NodularisImmunologyNov 2026
NCT07054034MG-ZG122 Humanized Monoclonal Antibody InjectionPhase 2Bronchial AsthmaRespiratoryMay 2027
NCT06837922MG-K10 Humanized Monoclonal Antibody InjectionPhase 3AsthmaRespiratoryNov 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aqualung Therapeutics Connect Biopharm PPD Development, LP Upstream Bio Celldex Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.